Limits...
Modifying the osteoblastic niche with zoledronic acid in vivo-potential implications for breast cancer bone metastasis.

Haider MT, Holen I, Dear TN, Hunter K, Brown HK - Bone (2014)

Bottom Line: The associated cancer-induced bone disease is treated with bone-sparing agents like zoledronic acid.The effects on growth plate cartilage were visualised by toluidine blue staining.The number of circulating tumour cells was reduced in ZOL treated animals.

View Article: PubMed Central - PubMed

Affiliation: CR-UK/YCR Cancer Research Centre, University of Sheffield, Sheffield, UK. Electronic address: mhaider1@sheffield.ac.uk.

Show MeSH

Related in: MedlinePlus

Effects of a single dose of zoledronic acid on bone architecture.μCT analysis was performed to assess the immediate effects of a single dose of zoledronic acid (100 μg/kg, i.p.) on bone volume and architecture. Proximal tibia (A,B) and distal femur (D,E) were analysed for trabecular bone (A, D) expressed as % bone volume/tissue volume and trabecular number (B,E). Representative cross sections of tibae are shown in (C). Two-way ANOVA and Bonferroni post-test: ****p ≤ 0.0001, ***p ≤ 0.001, **p ≤ 0.01. Day 1: n = 7, day 3: n = 7, day 5: n = 5 day 10: n = 5 for each time point and treatment group. All graphs show mean ± SEM.
© Copyright Policy - CC BY-NC-SA
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4127787&req=5

f0010: Effects of a single dose of zoledronic acid on bone architecture.μCT analysis was performed to assess the immediate effects of a single dose of zoledronic acid (100 μg/kg, i.p.) on bone volume and architecture. Proximal tibia (A,B) and distal femur (D,E) were analysed for trabecular bone (A, D) expressed as % bone volume/tissue volume and trabecular number (B,E). Representative cross sections of tibae are shown in (C). Two-way ANOVA and Bonferroni post-test: ****p ≤ 0.0001, ***p ≤ 0.001, **p ≤ 0.01. Day 1: n = 7, day 3: n = 7, day 5: n = 5 day 10: n = 5 for each time point and treatment group. All graphs show mean ± SEM.

Mentions: ZOL caused a significant increase in trabecular bone volume of proximal tibias from day 3 onwards when compared to control animals (PBS: 15.67% vs. ZOL: 18.92%; p ≤ 0.01; Fig. 2A). This increase was less prominent on day 5 but remained significantly elevated at day 10 (PBS: 15.35% vs. ZOL: 20.88%; p ≤ 0.0001; Fig. 2A). ZOL also significantly increased trabecular number by day 10 (PBS: 3.27 mm− 1 vs. ZOL: 4.45 mm− 1; p ≤ 0.01; Fig. 2B) when compared to PBS treatment. Representative cross sections of the proximal tibia illustrating this effect are shown in Fig. 2C.


Modifying the osteoblastic niche with zoledronic acid in vivo-potential implications for breast cancer bone metastasis.

Haider MT, Holen I, Dear TN, Hunter K, Brown HK - Bone (2014)

Effects of a single dose of zoledronic acid on bone architecture.μCT analysis was performed to assess the immediate effects of a single dose of zoledronic acid (100 μg/kg, i.p.) on bone volume and architecture. Proximal tibia (A,B) and distal femur (D,E) were analysed for trabecular bone (A, D) expressed as % bone volume/tissue volume and trabecular number (B,E). Representative cross sections of tibae are shown in (C). Two-way ANOVA and Bonferroni post-test: ****p ≤ 0.0001, ***p ≤ 0.001, **p ≤ 0.01. Day 1: n = 7, day 3: n = 7, day 5: n = 5 day 10: n = 5 for each time point and treatment group. All graphs show mean ± SEM.
© Copyright Policy - CC BY-NC-SA
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4127787&req=5

f0010: Effects of a single dose of zoledronic acid on bone architecture.μCT analysis was performed to assess the immediate effects of a single dose of zoledronic acid (100 μg/kg, i.p.) on bone volume and architecture. Proximal tibia (A,B) and distal femur (D,E) were analysed for trabecular bone (A, D) expressed as % bone volume/tissue volume and trabecular number (B,E). Representative cross sections of tibae are shown in (C). Two-way ANOVA and Bonferroni post-test: ****p ≤ 0.0001, ***p ≤ 0.001, **p ≤ 0.01. Day 1: n = 7, day 3: n = 7, day 5: n = 5 day 10: n = 5 for each time point and treatment group. All graphs show mean ± SEM.
Mentions: ZOL caused a significant increase in trabecular bone volume of proximal tibias from day 3 onwards when compared to control animals (PBS: 15.67% vs. ZOL: 18.92%; p ≤ 0.01; Fig. 2A). This increase was less prominent on day 5 but remained significantly elevated at day 10 (PBS: 15.35% vs. ZOL: 20.88%; p ≤ 0.0001; Fig. 2A). ZOL also significantly increased trabecular number by day 10 (PBS: 3.27 mm− 1 vs. ZOL: 4.45 mm− 1; p ≤ 0.01; Fig. 2B) when compared to PBS treatment. Representative cross sections of the proximal tibia illustrating this effect are shown in Fig. 2C.

Bottom Line: The associated cancer-induced bone disease is treated with bone-sparing agents like zoledronic acid.The effects on growth plate cartilage were visualised by toluidine blue staining.The number of circulating tumour cells was reduced in ZOL treated animals.

View Article: PubMed Central - PubMed

Affiliation: CR-UK/YCR Cancer Research Centre, University of Sheffield, Sheffield, UK. Electronic address: mhaider1@sheffield.ac.uk.

Show MeSH
Related in: MedlinePlus